Sanarus raises $3M to battle breast cancer

Sanarus Medical, maker of a device used to diagnose and treat breast cancer, brought in $3 million in convertible note funding from existing investors, reports VentureWire. It’s currently working on a product that uses ultrasound technology to detect the early stages of the disease.

The Pleasanton,… Continue Reading

Battle of the brain games: Lumos Labs raises $3 million, Fit Brains debuts

Battle of the brain games: Lumos Labs raises $3 million, Fit Brains debuts

The battle of the brain games is underway. Nintendo set this trend in motion when it launched “BrainAge” for the Nintendo DS in 2006. Since then, a number of startups have sprung up and launched additional games aimed at improving the cognitive abilities of gamers… Continue Reading

Live Gamer lands $24M for virtual good trading

Live Gamer lands $24M for virtual good trading

A new portal for trading virtual goods called Live Gamer announced its first funding today, promising to add some structure and protections to online transactions.

As massively multi-player online games (MMORPGS) like World of Warcraft have gained popularity, real-world markets have sprung up for everything from… Continue Reading

Life sciences briefing: Monday, Aug. 27, 2007

Life sciences briefing: Monday, Aug. 27, 2007

Featured companies: Bravo Health, InfraReDx, MedAssets, Prestwick Pharmaceuticals

Prestwick Pharma raises $20M for neuro drugs — Specialty pharma Prestwick Pharmaceuticals, a Washington, D.C., firm that acquires cast-off drug candidates to treat neurological conditions, raised $20 million from existing investors, VentureWire reports (subscription required). Among those participating in… Continue Reading

Horizon Therapeutics: Combining generic pain meds for greater drug safety

Horizon Therapeutics: Combining generic pain meds for greater drug safety

Palo Alto, Calif.-based Horizon Therapeutics, a biotech that aims to combine existing generic drugs to fight pain, raised $30 million in a third funding round. The company’s lead drug candidate, known only as HZT-501, is a “proprietary” combination of the generic drugs ibuprofen and famotidine,… Continue Reading

Ablation Frontiers raises $22M for treating arrythmia

Ablation Frontiers, a Carlsbad, Calif., developer of devices for treating irregular heartbeats known as cardiac arrythmias, raised $21.8 million in a third funding round. The Novartis Venture Fund led the round, joined by Affinity Ventures, Hexagon Investments, Trellis Health Ventures, Versant Ventures, Aberdare Ventures, and… Continue Reading

Paracor raises $44M for heart-failure device that restrains the heart

Paracor raises $44M for heart-failure device that restrains the heart

(UPDATED: See below.) Paracor Medical, a Sunnyvale, Calif., startup developing a mesh restraint designed to support failing hearts, raised $44.35 million in a fourth round of funding. The company is vying with another device startup, Acorn Cardiovascular, to prove that this sort of device works and to… Continue Reading

DiObex, a metabolic disease treatment co., raises $24M

DiObex, a San Francisco biopharmaceutical company focused on treatments of metabolic diseases, said it has raised $24 million in a second round of financing.

The round was led by Inventages Venture Capital (Switzerland). Also joining the round are new investors Mitsui Ventures (Japan) and Pac-Link BioVentures… Continue Reading

Summit Micro, a chip power management co., raises $10M

Summit Microelectronics, a Sunnyvale, Calif. maker of programmable power management integrated circuits, said it raised $10 million.

Nokia Growth Partners led with $4 million, and was joined by existing investors Norwest Venture Partners, August Capital, Pequot Ventures, Bessemer Venture Partners, Hotung Capital Management and others.

According… Continue Reading

Horizon Therapeutics, stomach ulcer treatment co., raises $15M

Horizon Therapeutics, a Palo Alto company close to bringing its stomach ulcer drug into the third and last set of clinical trials, said it has raised $15 million in a second round of funding.

Its lead product is HZT-501, a “GI-friendly” prescription NSAID.

Scale Venture Partners, formerly… Continue Reading